Anzeige
Mehr »
Sonntag, 31.08.2025 - Börsentäglich über 12.000 News
Wie SuperBuzz am Freitag parabolisch durchstartete - und warum das erst der Anfang sein könnte
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A40KLN | ISIN: US53271X1081 | Ticker-Symbol:
NASDAQ
29.08.25 | 22:00
2,710 US-Dollar
-1,81 % -0,050
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
LIMINATUS PHARMA INC Chart 1 Jahr
5-Tage-Chart
LIMINATUS PHARMA INC 5-Tage-Chart

Aktueller Chart LIMINATUS PHARMA Aktie

Chart vergleichen mit:

Firmenname, WKN, ISIN oder Aktien-Kürzel

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Devisen

Kurs

%

Rohstoffe

Kurs

%
Chart-Typ:
Zeitraum:
 
LIMINATUS PHARMA INC-Investoren interessieren sich auch für diese Wertpapiere
XFRA NEW INSTRUMENTS AVAILABLE ON 20.08.2025The following instruments on XETRA do have their first trading 20.08.2025 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag 20.08.2025 Aktien 1 US02155X2053 Alterity Therapeutics...
► Artikel lesen
ALTERITY THERAPEUTICS LIMITED: Appendix 4C - Q4 FY25 Quarterly Cash Flow ReportHighlights Granted U.S. FDA Fast Track Designation for ATH434 to treat Multiple System Atrophy (MSA)Reported positive topline data from open-label Phase 2 clinical trial of ATH434 in MSAPresented...
► Artikel lesen
ALTERITY THERAPEUTICS LIMITED: Alterity Therapeutics Reports Positive Topline Data from Open-Label Phase 2 Clinical Trial of ATH434 in Multiple System Atrophy- ATH434 Demonstrated Clinical Benefit on the Unified MSA Rating Scale and Global Measures of Neurological Symptoms - - Neuroimaging Biomarkers Showed Target Engagement and Slowed Brain Atrophy...
► Artikel lesen
SurgePays Accelerates Growth Across All Business Verticals; Reports Q2 2025 Results and Issues Revenue Guidance of $75M to $90M in 2025 and $225M to $240M in 2026BARTLETT, Tenn., Aug. 13, 2025 /PRNewswire/ -- SurgePays, Inc. (Nasdaq: SURG) ("SurgePays" or the "Company"), a wireless and point-of-sale technology company...
► Artikel lesen
SurgePays Reports First Quarter 2025 Financial ResultsAT&T Integration Complete; Nationwide Launch Positions Company for Most Aggressive Growth Phase to Date Company Ships Over 250,000 SIM Cards and Secures $6 Million...
► Artikel lesen
Pre-market Movers: OSR Holdings, SurgePays, Beeline Holdings, Humacyte, Tenon MedicalOTTAWA (dpa-AFX) - The following are some of the stocks making big moves in Wednesday's pre-market trading (as of 08.45 A.M. ET).In the Green OSR Holdings, Inc. (OSRH) is up over 173% at $4.37. SurgePays...
► Artikel lesen
Tenaya Therapeutics, Inc.: Tenaya Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business UpdateEnrollment Complete in Cohorts 1 and 2 of MyPEAK-1 Phase 1b/2 Trial of TN-201 for MYBPC3-associated HCM; Positive DSMB Safety Review Enables Enrollment of Expansion Cohorts Cohort 1 of RIDGE-1 Phase...
► Artikel lesen
Tenaya Therapeutics, Inc.: Tenaya Receives Positive Safety Reviews from Independent DSMBs to Advance Both TN-201 and TN-401 Gene Therapy Clinical Trials as DesignedEnrollment in Both Dose Cohorts of the MyPEAK-1 Phase 1b/2 Clinical Trial of TN-201 for Hypertrophic Cardiomyopathy (HCM) Complete; Follow-up Data from Cohort 1 and Initial Data from Cohort 2 Expected...
► Artikel lesen
Tenaya Therapeutics, Inc.: Tenaya Therapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)SOUTH SAN FRANCISCO, Calif., May 15, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially...
► Artikel lesen